HFX is a spinal cord stimulation (SCS) system made by Nevro that delivers electrical pulses at 10,000 Hz to interrupt pain signals before they reach the brain. Unlike older spinal cord stimulators that create a tingling or buzzing sensation called paresthesia, HFX therapy is paresthesia-free, meaning you feel pain relief without any unusual sensations. It’s FDA-cleared for chronic back and leg pain, non-surgical back pain, and painful diabetic neuropathy.
How HFX Works
A traditional spinal cord stimulator sends low-frequency electrical signals (typically 40 to 60 Hz) through leads placed near the spinal cord. These signals mask pain by replacing it with a tingling feeling. Some people find this tingling manageable, but many describe it as unpleasant, especially when it surges during movement, changes in position, or everyday activities like driving.
HFX operates at 10,000 Hz, roughly 200 times faster than traditional systems. At this frequency, the stimulation doesn’t produce any tingling at all. The leads are placed anatomically along the midline of the spine, spanning the T8 to T11 vertebrae, without needing the patient to be awake during surgery to map where the tingling lands. This simplifies the implant procedure and means lighter sedation isn’t required for intraoperative testing.
What the Clinical Evidence Shows
The largest head-to-head comparison, known as the SENZA-RCT, tested 10 kHz stimulation directly against traditional low-frequency SCS. At 12 months, 76.5% of patients receiving HFX therapy achieved at least 50% back pain relief, compared to 49.3% with traditional stimulation. For leg pain, the numbers were 72.9% versus 49.3%. These are meaningful differences, particularly for back pain, which has historically been harder to treat with older stimulators.
A separate 24-month study confirmed that pain relief from 10 kHz stimulation held steady over two years, suggesting the benefits don’t fade quickly once the device is implanted.
HFX for Diabetic Nerve Pain
One of the more striking uses for HFX is treating painful diabetic neuropathy, the burning, shooting nerve pain that develops in the feet and legs of some people with diabetes. A randomized clinical trial compared 10 kHz SCS plus standard medical management against standard medical management alone. At three months, 79% of patients in the stimulation group achieved at least 50% pain relief, compared to just 5% in the medication-only group.
The numbers at six months were even more telling. Average pain scores dropped from 7.6 out of 10 at baseline to 1.7 out of 10 in the stimulation group. Perhaps more surprising, 62% of patients in the HFX group showed measurable improvements on neurological exams, compared to 3% in the control group. This suggests the therapy may do more than just mask nerve pain.
The Trial Period Before Implant
You don’t go straight to a permanent implant. The process starts with a trial phase, where temporary leads are placed near your spinal cord and connected to an external device you wear for several days, typically five to seven. During this window, you and your doctor evaluate whether the stimulation provides meaningful relief. The general benchmark is at least 50% pain reduction.
Medicare and most private insurers require a successful trial before approving the permanent device. If a trial fails, a repeat attempt generally isn’t covered unless there were specific technical problems the first time around. Insurers also expect documentation showing you’ve tried and failed other pain treatments before spinal cord stimulation is considered. Medicare allows up to two trial procedures per spinal region over a patient’s lifetime, with the permanent implant limited to one per lifetime.
What Living With the Device Looks Like
The permanent HFX system consists of a small pulse generator (about the size of a deck of cards) implanted under the skin, typically near the hip or buttock, connected to thin leads in the epidural space of the spine. The newer HFX iQ model includes a smartphone app that uses algorithms to help personalize stimulation settings for your specific pain pattern.
The rechargeable battery lasts roughly 9 to 10 years before the generator needs to be surgically replaced. In the meantime, you’ll need to recharge it every few days using an external charging pad held against the skin. Most patients develop a routine, charging for 30 to 45 minutes every two to three days. Keeping the battery above 50% charge is generally recommended.
The system is MRI-conditional, meaning you can get full-body MRI scans at 1.5 Tesla and head or extremity scans at 1.5 or 3 Tesla, provided the leads are intact and impedance readings fall within normal range. If a lead fractures or disconnects from the battery, MRI safety is no longer guaranteed, so regular device checks matter.
Risks and Complications
Spinal cord stimulation carries a low risk of life-threatening complications, but hardware-related issues are relatively common. Across the broader SCS literature, complication rates range from about 5% to 40%, with most problems involving mechanical failures rather than infections or nerve injuries.
Lead migration is the most frequent issue, occurring in roughly 13% of patients across large reviews. When a lead shifts out of position, pain relief diminishes and a second surgery is usually needed to reposition it. Lead breakage is the next most common problem at about 9%. Less frequent risks include infection at the implant site, blood collection near the spine, and, rarely, a punctured lung if leads are placed in the upper thoracic region.
Because HFX leads are placed based on anatomy alone rather than requiring real-time feedback from the patient during surgery, the procedure is somewhat more straightforward than traditional SCS placement. However, the same hardware-related risks apply to any spinal cord stimulator regardless of the frequency it delivers.
Who Is a Candidate
HFX is typically considered for people with chronic pain that hasn’t responded adequately to more conservative treatments: physical therapy, medications, injections, and in some cases prior surgery. The most common candidates have chronic back pain with or without leg pain, failed back surgery syndrome, or painful diabetic neuropathy.
The trial phase serves as a built-in screening tool. If you don’t get significant relief during the trial, the temporary leads are simply removed and you avoid the commitment of a permanent implant. For people who do respond well, the combination of paresthesia-free therapy, strong clinical data, and the ability to undergo MRI scans makes HFX one of the more versatile options in the current spinal cord stimulation landscape.